Vera Therapeutics, Inc. SEC Filings

Vera Therapeutics (VERA) reported positive Phase 3 ORIGIN data for atacicept in IgA nephropathy, presented as a late-breaking oral at ASN Kidney Week 2025 and published in The New England Journal of Medicine. Participants on atacicept achieved a 46% reduction from baseline in proteinuria (24-hour UPCR) and a statistically significant, clinically meaningful 42% reduction versus placebo (p<0.0001) at week 36.

Efficacy was consistent across prespecified subgroups, including age, sex, race, region, baseline proteinuria, baseline eGFR, and baseline SGLT2i use. Secondary endpoints improved: Gd-IgA1 decreased by 68% and hematuria resolved in 81% of those with baseline hematuria. Safety across the ORIGIN program appears favorable and comparable to placebo, with fewer serious adverse events on atacicept (1 [0.5%]) than placebo (11 [5%]) and no deaths reported.

Vera Therapeutics (VERA) filed its Q3 2025 10‑Q, showing a larger quarterly net loss as it advances late-stage programs and scales operations. Net loss was $80.3 million (vs. $46.6 million a year ago), driven by higher operating expenses of $83.9 million with research and development at $56.5 million and general and administrative at $27.5 million. Basic and diluted net loss per share was $1.26.

Cash, cash equivalents and marketable securities were $497.4 million as of September 30, 2025, compared with $640.9 million at year-end 2024. Year-to-date net cash used in operating activities was $171.1 million. The company reiterated it believes its liquidity will fund operations for at least the next 12 months.

Vera refinanced its debt and entered a new loan facility of up to $500.0 million on June 2, 2025, with $75.0 million funded at closing and additional tranches available upon milestones and lender discretion. Long-term debt carried value was $74.6 million. The company highlighted positive primary endpoint results from the pivotal ORIGIN 3 Phase 3 trial of atacicept in IgAN and noted FDA Breakthrough Therapy Designation based on earlier Phase 2b data.

Vera Therapeutics (VERA) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The release is provided as Exhibit 99.1 and includes recent corporate updates.

The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. Item 9.01 lists the exhibits. The report was signed by Sean Grant, Chief Financial Officer, on November 5, 2025.

Kynam Capital Management, LP, Kynam Capital Management GP, LLC and individual Yue Tang report shared beneficial ownership of 3,426,887 shares of Vera Therapeutics Class A common stock, representing 5.37% of the class. The filing shows no sole voting or dispositive power; instead the reporting persons disclose shared voting and shared dispositive power over the full block of shares.

The signatories certify the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing identifies the reporting persons and their citizenships but does not name any group members or subsidiaries as acquiring parties.

Vera Therapeutics (Nasdaq: VERA) filed an 8-K announcing a new Sales Agreement with TD Securities (USA) LLC (TD Cowen) dated 5 Aug 2025. The arrangement establishes an at-the-market (ATM) equity program permitting the company to issue and sell up to $200 million of Class A common stock under its effective shelf registration statement (Form S-3, File No. 333-282861).

TD Cowen will act as sales agent and/or principal, executing ordinary-course, block or negotiated transactions on Nasdaq or other trading venues. The company will pay a commission of up to 3.0 % of gross proceeds. Vera is under no obligation to sell shares, and either party may terminate the agreement by written notice. The filing simultaneously terminates the prior Sales Agreement dated 3 Jun 2022.

The program enhances funding flexibility without adding debt but could create dilution and share-price overhang if the full $200 million capacity is utilized.

Vera Therapeutics (VERA) filed a Form 4 showing director Patrick G. Enright, through Longitude Prime Fund and Longitude Venture Partners IV, bought 250,000 Class A shares on 23–24 Jun 2025 at weighted-average prices of $20.87–$22.35, spending roughly $5.3 million. Post-transaction indirect holdings rise to 5,394,212 shares, an increase of about 4.9%. All trades were open-market purchases (code 'P'); no sales or derivatives were reported. Footnotes disclose price ranges and standard Section 16 disclaimers. The scale and direction of the trade suggest insider confidence, but the filing offers no strategic commentary.